Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel
NASDAQ:SVRA

Savara Q4 2025 Earnings Report

Savara logo
$5.14 +0.12 (+2.39%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Savara EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Savara Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Savara Announcement Details

Quarter
Q4 2025
Date
3/13/2026
Time
Before Market Opens
Conference Call Date
Friday, March 13, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Savara's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Savara's Q4 2025 Press ReleasePress Release
(8-K)
Savara's Q4 2025 Annual reportAnnual report
(10-K)

Savara Earnings Headlines

Savara (NASDAQ:SVRA) & Champions Oncology (NASDAQ:CSBR) Head-To-Head Comparison
May 24 at 4:47 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30797531
Savara Inc. (SVRA) Reports Q1 Financial Results
May 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/savara-inc-svra-reports-q1-financial-results-1767480/
More than 60 million Americans can position themselves before the 107x gold repricing.
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold reserves from $42 per ounce to today's market value - a potential 107x shift. President Trump has signaled interest in returning the dollar to commodity-backed foundations. More than 60 million Americans can move a portion of their savings into physical gold, tax-free and penalty-free, before any policy change is announced. The 2026 Gold Guide explains exactly how to position your 401(k) or IRA outside the dollar-denominated system.tc pixel
May 26 at 1:00 AM  |  Americas Gold Company (Ad)
5 Best Penny Stocks to Buy for Long Term
May 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-best-penny-stocks-to-buy-for-long-term-1765440/
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
May 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260520792505/en/savara-presented-new-biomarker-data-from-the-impala-2-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-the-american-thoracic-society-ats-international-conference-2026/
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...
May 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-exercise-capacity-data-185500185.html
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA) (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications.

Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.

View Savara Profile
Earnings Tools